Related Experiment Video
Updated: May 25, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Tedizolid (TR-701): a new oxazolidinone with enhanced potency
Zeina A Kanafani1, G Ralph Corey
1American University of Beirut Medical Center, Beirut, Lebanon. zk10@aub.edu.lb
Introduction:
Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid.
Areas Covered:
This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed.
Expert Opinion:
Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Antimicrobial Effectiveness
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antibiotic Selection
Inhibitors of Bacterial Protein Synthesis
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

